FY2025 · ended Dec 31, 2025 · Revenue $116.59M, +10.2% YoY · Filed Mar 13, 2026
Gyre Therapeutics, Inc. (GYRE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $116.6 million and net income of $9.9 million. Free cash flow was -$180,000. As of Jun 30, 2026 it held $58.9 million in cash and investments and $3.4 million in total debt.
Revenue (TTM)
$109.82M
-3.4% vs year-ago TTM
Net income (TTM)
$-28.22M
-424.4% vs year-ago TTM
Operating cash flow (TTM)
$-4.93M
+42.8% vs year-ago TTM
Free cash flow (TTM)
$-6.11M
+37.2% vs year-ago TTM
EPS (TTM)
$-0.19
-1627.7% vs year-ago TTM
Dividend per share
$0.24
Shares outstanding
96.96M
+3.6% vs prior year
Net cash
$55.53M
as of Jun 30, 2026
Operating margin
-20.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1124105
- Former names
- CATALYST BIOSCIENCES, INC. (until Oct 27, 2023); TARGACEPT INC (until Aug 19, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M | — | $7.3M |
| Operating income | $11.5M | $16.2M | -$67.2M | $9.2M | -$87.9M |
| Net income | $9.9M | $17.9M | -$85.5M | $4.3M | -$87.9M |
| Diluted EPS | $0.02 | $0.05 | -$1.41 | $0.03 | — |
| Operating cash flow | $1.0M | -$3.6M | $25.9M | $10.7M | -$83.8M |
| Free cash flow | -$180,000 | -$6.0M | $17.4M | — | -$84.6M |
| Total assets | $166.1M | $125.4M | $116.5M | $84.8M | $55.7M |
| Total liabilities | $23.9M | $27.0M | $38.1M | $12.5M | $14.6M |
| Stockholders' equity | $106.0M | $63.3M | -$15.8M | $42.5M | $41.1M |
| Cash and investments | $54.0M | $26.7M | $62.8M | $25.2M | $46.9M |
| Total debt | $939,000 | $1.6M | $409,000 | $38,000 | $2.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 22, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 1, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 26, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
All 1001 Gyre Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.